Chromogranin A: A novel susceptibility gene for essential hypertension

Bhavani S Sahu, Parshuram J. Sonawane, Nitish R. Mahapatra

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Chromogranin A (CHGA) is ubiquitously expressed in secretory cells of the endocrine, neuroendocrine, and neuronal tissues. Although this protein has long been known as a marker for neuroendocrine tumors, its role in cardiovascular disease states including essential hypertension (EH) has only recently been recognized. It acts as a prohormone giving rise to bioactive peptides such as vasostatin-I (human CHGA1-76) and catestatin (human CHGA352-372) that exhibit several cardiovascular regulatory functions. CHGA is over-expressed but catestatin is diminished in EH. Moreover, genetic variants in the promoter, catestatin, and 3'-untranslated regions of the human CHGA gene alter autonomic activity and blood pressure. Consistent with these findings, targeted ablation of this gene causes severe arterial hypertension and ventricular hypertrophy in mice. Transgenic expression of the human CHGA gene or exogenous administration of catestatin restores blood pressure in these mice. Thus, the accumulated evidence establishes CHGA as a novel susceptibility gene for EH.

Original languageEnglish (US)
Pages (from-to)861-874
Number of pages14
JournalCellular and Molecular Life Sciences
Issue number6
StatePublished - Mar 1 2010


  • Anti-hypertensive
  • Blood pressure
  • Cardiovascular
  • Catestatin
  • Chromogranin A
  • Genetics
  • Hypertension
  • Vasostatin

Fingerprint Dive into the research topics of 'Chromogranin A: A novel susceptibility gene for essential hypertension'. Together they form a unique fingerprint.

Cite this